Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of OBP-301 + atezolizumab + chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
jRCT2063200044Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev, atezolizumab and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary safety observation. Started Dec 2021; status: completed.
02
Drugs
suratadenoturevatezolizumabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2063200044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063200044.